RXRA and type 2 diabetes mellitus: On the other hand, osteoarthritis (210 fold), mammalian target of rapamycin (mTOR-201 fold), IL-8 (197 fold), Th1-Th2 (185 fold), PPARα/RXRα activation (180 fold), NF-κB (181 fold), IL-6 (128 fold), Type II diabetes mellitus signaling (128 fold), and nitric oxide signaling in cardiovascular system (113 fold), all have lower fold change expression compared to EIF2.